What You Should Know:
– Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced a collaboration with Dr. C. Ola Landgren, MD, PhD, head of one of the world’s leading myeloma computational and translational research laboratories.
-Dr. Landgren’s team, including Dr. David Coffey and Dr. Benjamin Diamond, at the University of Miami’s Sylvester Comprehensive Cancer Center, will work together to generate clinical data sets using Mission Bio’s Tapestri Single-cell DNA Multiple Myeloma Panel to examine Multiple Myeloma (MM) at an unprecedented level of clonal detail, promising to reveal new insights that may potentially improve outcomes for MM patients.
Advancing Multiple Myeloma Research with Single-Cell DNA and Multiomics Analysis
Mission Bio, a pioneering life science company, specializes in advancing single-cell DNA and multiomics analysis through its innovative Tapestri Platform. This technology delivers unmatched granularity and precision essential for complex fields such as cancer research, pharmaceutical development, and advanced cell and gene therapies. By surpassing traditional methods like bulk sequencing, Tapestri enables researchers to:
– Identify rare cell populations,
– Uncover mechanisms of therapeutic resistance and response, and
– Establish critical quality metrics for next-generation medical treatments.
The Challenge of Multiple Myeloma (MM)
Multiple myeloma (MM), a challenging and currently incurable blood cancer, affects approximately 230,000 individuals globally. Relapse poses a significant problem, with 50% of patients experiencing relapse within the first year of frontline therapy. Current treatments leave only 20% of relapse patients surviving beyond five years. A critical factor in relapse is the presence of resistant clones—cells with mutations or alterations that allow them to evade treatment.
Enhancing MM Research Through Collaboration
Mission Bio, in collaboration with the University of Miami, aims to address the limitations of current tools that inadequately profile MM progression from early clone emergence to advanced disease. The project focuses on:
– Predicting relapse risk in patients and guiding subsequent treatment strategies,
– Exploring the potential of blood samples as a non-invasive alternative to bone marrow samples, improving accessibility and patient comfort.
By leveraging clinical samples and the precision of the Tapestri Platform, this initiative seeks to revolutionize MM diagnostics and treatment, ultimately contributing to better patient outcomes and advancing the field of personalized medicine.
“We recognize that Multiple Myeloma is a genetically complex disease that hasn’t been easy to comprehend fully using existing methods, particularly when it comes to the crucial questions of when patients might experience relapse and what clinicians should do next when relapse occurs,” said Dr. Landgren. “Our aim is to utilize Tapestri to better understand Multiple Myeloma disease heterogeneity, which in turn will allow us to detect and treat relapse faster. Ultimately, we hope to demonstrate the clinical feasibility of the Multiple Myeloma assay and to facilitate the establishment of Tapestri to advance outcomes for patients.”
